The agenda includes:
Preparing a position on the evaluation of the drug: Ozurdex (dexamethasonum) under the drug programme “Treatment of uveitis (ZBN) – intermediate part, posterior segment or entire uvea (ICD-10 H 20.0, H 30.0)”.
Preparing an opinion on the legitimacy of introducing changes in the current description of the B.44 drug programme. “Management of patients with severe asthma (ICD-10: J45, J82)”.
Preparing an opinion on the legitimacy of introducing changes in the current description of the B.82 drug programme. “Treatment of patients with the active form of spondyloarthritis (SpA) without radiographic changes characteristic of AS (ICD-10: M46.8)”.
Preparing an opinion by the Transparency Council on the active substance etanercept in the off-label indication for use in peripheral SpA form under the B.82 drug programme.
Preparing a position on the legitimacy of granting consent for reimbursement of Fycompa (perampanelum) in the indications: drug-resistant epilepsy, drug-resistant epilepsy with focal seizures.
Preparing a position on the legitimacy of granting consent for reimbursement of Inovelon (rufinamidum) in the indications: drug-resistant epilepsy; Lennox-Gastaut syndrome; West syndrome; Rasmussen syndrome.
Preparing an opinion on draft health policy programmes of local government units:
- “Programme for the prevention and early detection of breast cancer in women over 25 years of age living in the Municipality of Toszek”,
- “Co-financing for infertility treatment by in vitro fertilization for the residents of Rzeszów for the period 2022-2025″,
“Programme for prevention and early detection of thyroid diseases for the period 2023-2025″ (Town of Leszno).